Abstract：
Osimertinib has demonstrated efficacy as the first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. However, EGFR-mutant NSCLC cells often acquire resistance to osimertinib. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (BRAF V600E) was detected in a re-biopsy (LC-SCRUM-TRY testing) of a patient with advanced lung adenocarcinoma who was resistant to osimertinib treatment. Currently, the patient is receiving dabrafenib/trametinib combination therapy and is under observation; a slight shrinking effect of cancer has been observed.
摘要：
Osimertinib已被证明是具有表皮生长因子受体（EGFR）基因突变的晚期非小细胞肺癌（NSCLC）的一线和二线治疗方法。然而,EGFR突变的NSCLC细胞通常获得对奥希替尼的耐药性。在对奥希替尼治疗耐药的晚期肺腺癌患者的重新活检（LC-SCRUM-TRY检测）中检测到V-Raf鼠肉瘤病毒癌基因同源物B1（BRAF）突变（BRAFV600E）。目前,患者正在接受dabrafenib/trametinib联合治疗，并且正在观察中；已观察到癌症的轻微收缩作用。
